Lillian Lian

Counsel, Corporate

Bio

Lillian Lian has extensive experience in corporate finance transactions, initial public offerings, spin-offs, mergers and acquisitions, compliance and Hong Kong regulatory matters. She has worked with clients across a broad spectrum of industries, including technology, health care, consumer products, energy and mining, insurance and securities.

Ms. Lian’s experience (including prior to joining Skadden) includes:

Capital Markets

  • Bilibili in its US$1.6 billion sustainable convertible notes offering;
  • MicroTech Medical in its US$233 million initial public offering and listing on the Hong Kong Stock Exchange;
  • Abbisko in its US$225 million initial public offering and listing on the Hong Kong Stock Exchange;
  • Helens in its US$323 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriter);
  • Kindstar Global in its US$284 million initial public offering and listing on the Hong Kong Stock Exchange;
  • Zylox-Tonbridge in its US$329 million initial public offering and listing on the Hong Kong Stock Exchange;
  • Nayuki in its US$656 million initial public offering and listing on the Hong Kong Stock Exchange;
  • CARsgen Therapeutics in its US$400 million initial public offering and listing on the Hong Kong Stock Exchange;
  • Bairong in its US$507 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • New Horizon Health in its US$263 million initial public offering and listing on the Hong Kong Stock Exchange;
  • RemeGen in its US$514 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • JW Therapeutics in its US$300 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • Ocumension Therapeutics in its US$200 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • Shenzhen Hepalink Pharmaceutical in its US$523 million initial public offering and listing on the Hong Kong Stock Exchange;
  • NetEase in its US$3.1 billion secondary listing on the Hong Kong Stock Exchange (representing the underwriters);
  • Legend Biotech in its listing on Nasdaq through a spin-off from Genscript (representing the underwriters);
  • Haitong UniTrust International Leasing in its spin-off from Haitong Securities and US$298 million initial public offering and listing on the Hong Kong Stock Exchange;
  • Meituan Dianping in its US$4.2 billion initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • Ping An Healthcare and Technology in its spin-off from Ping An Insurance and US$1.1 billion initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • CSC Financial Co., Ltd in its US$915 million initial public offering and listing on the Hong Kong Stock Exchange;
  • Orient Securities in its US$876 million initial public offering and listing on the Hong Kong Stock Exchange;
  • China Development Bank Financial Leasing Co. in its US$776 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • BAIOOO Family Interactive Limited in its US$196 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • China Galaxy Securities Co., Ltd. in its US$1.1 billion initial public offering and listing on the Hong Kong Stock Exchange;
  • Chinalco Mining Corporation International in its US$438 million initial public offering and listing on the Hong Kong Stock Exchange;
  • China Pacific Insurance in its US$3.1 billion initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • Fosun International Limited in its US$1.7 billion initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
  • China Oilfield Services Limited in its HK$5.8 billion placing of new shares;
  • China Investment Corporation in its HK$3.1 billion block trade;
  • China National Building Material Company in its HK$3.8 billion placing of new shares; and
  • China Power New Energy Development Company in its HK$2.1 billion placing of new shares to China Three Gorges Corporation;

Mergers and Acquisitions

  • CNOOC in its US$5.1 billion acquisition of Nexen Inc.;
  • Koninklijke Philips Electronics NV in the sale of its color TV business in China to TPV Technology Limited; and
  • China Power International Development Limited in its US$650 million acquisition of Wu Ling Power;

Compliance

  • Various Hong Kong-listed companies in relation to their compliance matters under the Hong Kong Listing Rules and other relevant laws and regulations, including the Securities and Futures Ordinance, the Companies Ordinance and the Takeovers Code.

Credentials

Education

  • Postgraduate Certificate In Laws, University of Hong Kong, 2008
  • G.D.L., BPP Law School, 2006

Lillian Lian